<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02743650</url>
  </required_header>
  <id_info>
    <org_study_id>81006</org_study_id>
    <nct_id>NCT02743650</nct_id>
  </id_info>
  <brief_title>Pilot Study of Sodium Bicarbonate in Generally Healthy People With Low Bicarbonate</brief_title>
  <official_title>Pilot Study of Sodium Bicarbonate in Generally Healthy People With Low Bicarbonate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The University of Utah Center on Aging</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this pilot study is to determine whether oral sodium bicarbonate can raise low
      serum bicarbonate concentration in people without chronic kidney disease (CKD). Participants
      will take sodium bicarbonate for six weeks, followed by a four week washout period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CKD affects 25 million Americans and the risks of cardiovascular morbidity, hospitalizations,
      and death are substantially higher for people with CKD. Furthermore, 6% of the total Medicare
      budget is spent on 600,000 people with end-stage renal disease. Thus, CKD is highly
      prevalent, associates with poor outcomes, and is a tremendous financial burden to society.

      Apart from treating hypertension and diabetes, there are no therapies that prevent CKD.
      However, results from two studies have found that low serum bicarbonate levels increase risk
      of developing CKD, which suggests that normalizing low serum bicarbonate may prevent CKD.

      One way to raise low serum bicarbonate is by taking sodium bicarbonate. Whether sodium
      bicarbonate, which is commonly prescribed to raise low serum bicarbonate in people with CKD,
      can raise low bicarbonate in people without CKD is uncertain because the reason bicarbonate
      is low in people without CKD is unclear. This is because low bicarbonate by itself cannot
      distinguish whether the acid-base abnormality is primary metabolic acidosis or respiratory
      alkalosis. The former process is readily corrected with alkali. However, the administration
      of alkali in the latter situation may not raise bicarbonate concentration.

      Therefore, the purpose of this pilot study is to determine whether oral sodium bicarbonate
      can raise low serum bicarbonate in people without renal disease.

      The study is a single-arm open label study of 15 individuals without CKD with low serum
      bicarbonate concentration. The study duration is 10 weeks. After completing the baseline
      visit, participants will take oral sodium bicarbonate (initial dose level: 0.3
      milliequivalents per kilogram per day (mEq/kg/d) for 6 weeks (On-treatment period), followed
      by a 4 week Off-treatment period. Serum concentrations of sodium bicarbonate will be tested
      during the treatment period, at the end of the On-treatment period (Week 6) and at the end of
      the Off-treatment period (Week 10).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum bicarbonate concentration from baseline to 6 weeks</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Comparison of pre-intervention serum bicarbonate levels to week 6 levels following treatment with oral sodium bicarbonate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum bicarbonate concentration after 4 weeks of stopping sodium bicarbonate treatment</measure>
    <time_frame>Baseline, 6 weeks and 10 weeks</time_frame>
    <description>Comparison of serum bicarbonate levels four weeks after discontinuing oral sodium bicarbonate treatment to pre-intervention (baseline) and immediate post-treatment (week 6) serum bicarbonate levels.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Sodium Bicarbonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive oral sodium bicarbonate for 6 weeks (On-treatment period). After the 6 week visit, participants will stop taking sodium bicarbonate and return for a final visit 4 weeks later (Off-treatment period).
The initial dose of sodium bicarbonate prescribed is 0.3 mEq/kg/d. If a subject meets the protocol criteria, the dose will be increased to 0.6 mEq/kg/d. Half the dose will be taken by mouth in the morning and the other half in the evening.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sodium bicarbonate</intervention_name>
    <description>The initial dose of sodium bicarbonate is 0.3 mEq/kg/d. If a subject meets the protocol criteria, the dose will be increased to 0.6 mEq/kg/d.</description>
    <arm_group_label>Sodium Bicarbonate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Estimated glomerular filtration rate (eGFR) ≥ 60 ml/min/1.73m2

          -  Urinary albumin/creatinine ratio &lt; 30 mg/gm

          -  Serum bicarbonate ≤ 23 mEq/L (average of the two most recent measurements within the
             past year)

          -  Age ≥ 50 years

        Exclusion Criteria:

          -  Blood pressure ≥ 160/100 mm Hg

          -  Serum potassium &lt; 3.5 mEq/L

          -  New York Heart Association Class 3 or 4 heart failure symptoms

          -  Chronic oxygen therapy

          -  Chronic obstructive pulmonary disease requiring daily bronchodilator or prednisone
             therapy

          -  Weight ≥ 160 kg

          -  Use of sodium bicarbonate, sodium citrate, potassium citrate, or potassium bicarbonate
             within the previous two weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kalani L Raphael, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Salt Lake City Healthcare System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kalani L Raphael, MD</last_name>
    <phone>801-582-1565</phone>
    <phone_ext>1794</phone_ext>
    <email>kalani.raphael@hsc.utah.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer L Zitterkoph</last_name>
    <phone>801-585-1897</phone>
    <email>jennifer.zitterkoph@hsc.utah.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VA Salt Lake City Healthcare System</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kalani L Raphael, MD</last_name>
      <phone>801-582-1565</phone>
      <phone_ext>1794</phone_ext>
      <email>kalani.raphael@hsc.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer L Zitterkoph</last_name>
      <phone>801-585-1897</phone>
      <email>jennifer.zitterkoph@hsc.utah.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kalani L Raphael, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Goldenstein L, Driver TH, Fried LF, Rifkin DE, Patel KV, Yenchek RH, Harris TB, Kritchevsky SB, Newman AB, Sarnak MJ, Shlipak MG, Ix JH; Health ABC Study Investigators. Serum bicarbonate concentrations and kidney disease progression in community-living elders: the Health, Aging, and Body Composition (Health ABC) Study. Am J Kidney Dis. 2014 Oct;64(4):542-9. doi: 10.1053/j.ajkd.2014.05.009. Epub 2014 Jun 18.</citation>
    <PMID>24953890</PMID>
  </reference>
  <reference>
    <citation>Driver TH, Shlipak MG, Katz R, Goldenstein L, Sarnak MJ, Hoofnagle AN, Siscovick DS, Kestenbaum B, de Boer IH, Ix JH. Low serum bicarbonate and kidney function decline: the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis. 2014 Oct;64(4):534-41. doi: 10.1053/j.ajkd.2014.05.008. Epub 2014 Jun 18.</citation>
    <PMID>24953891</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2016</study_first_submitted>
  <study_first_submitted_qc>April 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2016</study_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Kalani Raphael</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Low Serum Bicarbonate Level</keyword>
  <keyword>Sodium Bicarbonate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

